Puretech Health Stock Price, News & Analysis

PureTech Health (Nasdaq: PRTC) has appointed Julie Krop, M.D. as Chief Medical Officer, overseeing clinical development for its expanding pipeline. Dr. Krop brings extensive experience, having led the development of eight therapeutics reaching Phase 3, with three achieving FDA approval. Her expertise will be pivotal for advancing the lead program, LYT-100, towards potential registration in treating idiopathic pulmonary fibrosis. PureTech has a robust pipeline of 26 therapeutic candidates, including two with regulatory approvals.

PureTech Health (Nasdaq: PRTC) announced that Imbrium Therapeutics has exercised a license option to develop LYT-503/IMB-150, a non-opioid candidate for interstitial cystitis/bladder pain syndrome. This collaboration includes a $6.5 million option exercise payment, with potential for up to $53 million in milestone payments and royalties on sales. An IND application for LYT-503/IMB-150 is expected in early 2022. The drug aims to target inflamed bladder tissue while minimizing systemic exposure, addressing a significant unmet medical need.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) plans to announce its half-yearly results for the six months ended June 30, 2021, on August 24, 2021. A presentation and conference call for analysts will occur at 9:00am EDT / 2:00pm BST on the same day. PureTech is a clinical-stage biotherapeutics company focused on developing innovative treatments for severe diseases across various medical fields. The company’s pipeline includes 26 therapeutics and candidates, with two securing FDA clearance and European marketing authorization. More details can be found on their website.

PureTech Health (Nasdaq:PRTC) announced that its Founded Entity, Akili Interactive, has launched new gaming features for its FDA-cleared EndeavorRx treatment aimed at children with ADHD. This update enhances user engagement and personalization without altering its patented core technology, the Selective Stimulus Management Engine (SSME™). These improvements are informed by user insights and latest trends in gaming development, marking a significant step in Akili's go-to market strategy to scale usage among families and healthcare professionals.

PureTech Health (Nasdaq: PRTC) announces that its Founded Entity, Vedanta Biosciences, has completed a $68 million Series D financing led by Magnetar Capital and includes a $25 million investment from Pfizer. The funds will support Vedanta's clinical trials, including advancing VE303 into a Phase 3 trial for Clostridioides difficile infection and initiating a Phase 2 trial for VE202 in ulcerative colitis. Vedanta's pipeline focuses on defined bacterial consortia therapies, addressing various diseases, with results expected in Q3 2021.

PureTech Health plc (Nasdaq: PRTC) announced a definitive agreement for its Founded Entity, Gelesis, Inc., to merge with Capstar Special Purpose Acquisition Corp. (NYSE: CPSR). This transaction aims to list the combined company on the NYSE under the symbol 'GLS' and has an implied enterprise value of approximately $1.0 billion. Gelesis expects to secure up to $376 million in gross proceeds, primarily for the commercial launch of its FDA-cleared weight management product, Plenity. This merger showcases PureTech's unique model for creating value through its Founded Entities.

PureTech Health plc (Nasdaq: PRTC) announces a collaboration between its Founded Entity, Vor Biopharma (Nasdaq: VOR), and Janssen Biotech, Inc.. The partnership aims to explore combining Vor's engineered hematopoietic stem cell transplant platform with Janssen's bi-specific antibodies targeting acute myeloid leukemia (AML). Each company retains ownership of its respective technologies. Vor's Chief Scientific Officer expressed enthusiasm about leveraging both technologies to improve cancer treatment while minimizing side effects. This collaboration is a significant step in advancing innovative cancer therapies.

PureTech Health (PRTC) announced that its Founded Entity, Sonde Health, will collaborate with Qualcomm to enhance Sonde's vocal biomarker technology for the Snapdragon 888 and 778G 5G Mobile Platforms. This partnership aims to integrate machine learning-driven vocal biomarker capabilities into mobile and IoT devices, potentially enabling various health monitoring applications on millions of devices. Sonde’s technology can detect conditions like asthma and COVID-19 through voice analysis, paving the way for innovative, native health features directly on devices, ensuring faster and more secure health monitoring.

PureTech Health plc (Nasdaq: PRTC) has announced a clinical trial and supply agreement with BeiGene to evaluate tislelizumab, an anti-PD-1 immune checkpoint inhibitor, in combination with PureTech’s investigational monoclonal antibody LYT-200. This collaboration aims to address difficult-to-treat solid tumors. PureTech will control the LYT-200 program and expects to report topline Phase 1 results in Q4 2021. Tislelizumab is approved in China for multiple solid tumor indications, with ongoing trials aimed at expanding its use.